May 21, 2018
The LSU Health Foundation New Orleans and the Foundation Board of Directors have announced an investment in Oleander Medical Technologies LLC, as the company takes the next step in the development of a revolutionary treatment for advanced cancer. The new treatment is engineered to destroy many of the most invasive and deadly cancers, including mesothelioma, and cancers of the lung, breast, colon, and prostate, using a process called Targeted Osmotic Lysis (TOL)™.
This is the first investment of its kind by the LSU Health Foundation New Orleans.
The Oleander Medical Technologies leadership team includes two LSU Health New Orleans-based faculty members: Dennis Paul, Ph.D., who is a co-founder and managing member, and serves as chief science officer at Oleander; and Harry J. Gould, III, M.D., Ph.D., also a co-founder and managing member, and who serves as chief medical officer at Oleander.
Paul is Professor of Pharmacology and Experimental Therapeutics at LSU Health New Orleans. He holds a doctorate from the University of British Columbia and completed post-doctoral training at the Memorial Sloan-Kettering Cancer Center. Dr. Gould is Professor of Neurology and Neuroscience, holds a doctorate from Brown University, received his medical degree from LSU Health Sciences Center in New Orleans, and is board certified in Neurology and Pain Management.
“LSU Health Foundation New Orleans strives to establish partnerships and invest in research technologies that aid, assist or supplement the work of LSU Health New Orleans’ talented research and medical faculty. This exciting opportunity represents the first step into Foundation-funded, faculty-driven partnerships, utilizing our mission-related impact investment pool with the expectation that investments like this will speed positive outcomes in the fight against cancer and other innovative breakthroughs,” said LSU Health Foundation New Orleans President and CEO Matthew Altier.
“In recognition of the importance of this kind of partnership, the Foundation engaged a panel of experts including a geneticist, a neurosurgeon, an oncologist, and a cardiologist who thoroughly investigated the science before moving forward with the investment in Oleander Medical Technologies,” said LSU Health Foundation New Orleans Board Chairman Carroll Suggs.
“Louisiana has one of the highest rates of cancer in the country. It is fitting that local scientists and local investors, like the LSU Health Foundation, are joining together to work on this revolutionary treatment for advanced cancers right here in Louisiana,” said Oleander Medical Technologies President Paige Miller.
About LSU Health Foundation, New Orleans
The LSU Health Foundation New Orleans exists to support LSU Health New Orleans and its fourfold mission of patient care, education, research, and community outreach through fundraising, asset oversight and management, and the unification of donor passions with institutional priorities. Working together, all three contribute to the success of LSU Health New Orleans as it strives to Discover, Teach, Heal, and Serve. More information about this and other philanthropic opportunities at LSU Health New Orleans may be found at: www.lsuhealthfoundation.org.
About Oleander Medical Technologies
Oleander Medical Technologies is an LSU firm developing a revolutionary new treatment to destroy many of the most invasive and deadly cancers using a process called Targeted Osmotic Lysis (TOL)™. More information about TOL may be found at: www.oleandermedicaltechnologies.com